Evidence map›Paper›PMID 36174360›Full record

ArticleBiosensors & bioelectronics2022

Ultrasensitive monitoring of SARS-CoV-2-specific antibody responses based on a digital approach reveals one week of IgG seroconversion.

Feiyang Ou, Danyun Lai, Xiaojun Kuang, Ping He, Yang Li, He-Wei Jiang, Wei Liu, Hongping Wei, Hongchen Gu, Yuan Qiao Ji and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors & bioelectronics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Feiyang OuSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200030, China.
Danyun LaiShanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China.
Xiaojun KuangSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200030, China.
Ping HeCAS Key Laboratory of Special Pathogens and Biosafety, Centre for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Yang LiShanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China.
He-Wei JiangShanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China.
Wei LiuHangzhou Joinstar Biotechnology Co., Ltd. Hangzhou, 310000, China.
Hongping WeiCAS Key Laboratory of Special Pathogens and Biosafety, Centre for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Hongchen GuSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200030, China.
Yuan Qiao JiYK Pao School, Shanghai, 201620, China.
Hong XuSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200030, China. Electronic address: xuhong@sjtu.edu.cn.
Sheng-Ce TaoShanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China. Electronic address: taosc@sjtu.edu.cn.
Shanghai Jiao Tong University · CNChinese Academy of Sciences · CNShanghai American School · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is still unfolding, while many people have been vaccinated. In comparison to nucleic acid testing (NAT), antibody-based immunoassays are faster and more convenient. However, its application has been hampered by its lower sensitivity and the existing fact that by traditional immunoassays, the measurable seroconversion time of pathogen-specific antibodies, such as IgM or IgG, lags far behind that of nucleic acids. Herein, by combining the single molecule array platform (Simoa), RBD, and a previously identified SARS-CoV-2 S2 protein derivatized 12-aa peptide (S2-78), we developed and optimized an ultrasensitive assay (UIM-COVID-19 assay). Sera collected from three sources were tested, i.e., convalescents, inactivated virus vaccine-immunized donors and wild-type authentic SARS-CoV-2-infected rhesus monkeys. The sensitivities of UIM-COVID-19 assays are 100-10,000 times higher than those of conventional flow cytometry, which is a relatively sensitive detection method at present. For the established UIM-COVID-19 assay using RBD as a probe, the IgG and IgM seroconversion times after vaccination were 7.5 and 8.6 days vs. 21.4 and 24 days for the flow cytometry assay, respectively. In addition, using S2-78 as a probe, the UIM-COVID-19 assay could differentiate COVID-19 patients (convalescents) from healthy people and patients with other diseases, with AUCs ranging from 0.85-0.95. In summary, the UIM-COVID-19 we developed here is a promising ultrasensitive biodetection strategy that has the potential to be applied for both immunological studies and diagnostics.

Indexed as

Biosensing TechniquesCOVID-19Nucleic AcidsVaccinesAntibodies, ViralAntibody FormationHumansImmunoglobulin GImmunoglobulin MSARS-CoV-2Sensitivity and SpecificitySeroconversionAntibodies, ViralImmunoglobulin GImmunoglobulin MNucleic AcidsVaccinesCOVID-19DiagnosticExtreme early-stage seroconversionIgG/IgM antibodiesUltrasensitive digital detection

Identifiers

PMID36174360
PMCPMC9476360
OpenAlexW4295921477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.